Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2/3 1

Status

Completed 4Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2Other solid neoplasm 1

Conditions

Uveal Melanoma 2Retinal Diseases 1Melanoma 1Macular Degeneration 1Choroid Diseases 1

Interventions

Nivolumab 27pembrolizumab 22Ipilimumab 17Temozolomide 13toripalimab 12Biopsy 10Cyclophosphamide 9Imiquimod 8Dacarbazine 7Blood Specimen Collection 7camrelizumab 6Chemotherapy, Adjuvant 6trametinib 5fludarabine 5dabrafenib 5atezolizumab 5aldesleukin 5Gene Expression Profiling 5Cisplatin 5Aminolevulinic Acid 5fludarabine phosphate 4durvalumab 4binimetinib 4apatinib 4Tomography, Optical Coherence 4Sorafenib 4Photochemotherapy 4Interleukin-2 4Injections 4Carboplatin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Ranibizumab × Dermatologic × Clear all
NCT00811200 2009-07-02

TORR

Leiden University Medical Center

Phase 2/3 Unknown
220 enrolled
Dermatologic

Uveal Melanoma, Macular Degeneration, Melanoma, Retinal Diseases, Choroid Diseases

NCT00540930 2007-10-08

Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy

Shields, Shields and Associates

Phase 4 Unknown
400 enrolled
Dermatologic

Uveal Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡